Wednesday, July 8, 2026

Drug profile · INN

icosapent ethyl

icosapent ethyl (VAZKEPA) is a unknown. Associated with Seqirus (Australia) Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Cardiovascular system (C10) C10AX
US status approved
Patents linked 0
Pipeline programs 1
News articles 1
Drug details — icosapent ethyl

Quick answer

icosapent ethyl (VAZKEPA) is a unknown. Associated with Seqirus (Australia) Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN icosapent ethyl
Brand VAZKEPA
Mechanism Unknown
Therapeutic class Cardiovascular system (C10)
Route ORAL
Formulation CAPSULE
ATC code C10AX

Mechanism of action

Unknown

Approval history

Authority Status Date
FDA approved
EMA approved
TGA approved

Recent coverage

Pipeline programs

  1. Icosapent (MND-2119) Phase 3 · Mochida Pharmaceutical · Hypertriglyceridemia

Related & competitor drugs

  1. alirocumab Cardiovascular system (C10)
  2. aliskiren Cardiovascular system (C09)
  3. azilsartan medoxomil Cardiovascular system (C09)
  4. bempedoic acid Cardiovascular system (C10)
  5. bosentan Cardiovascular system (C02)
  6. dofetilide Cardiovascular system (C01)

Frequently asked questions

What is icosapent ethyl?

icosapent ethyl (VAZKEPA) is a unknown. Associated with Seqirus (Australia) Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for icosapent ethyl?

VAZKEPA is a marketed brand name for icosapent ethyl. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of icosapent ethyl?

icosapent ethyl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.